Fresh2 Group Ltd ADR FRES
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Fresh2 Group Ltd. Announces Receipt of an Additional Delinquency Compliance Alert Notice from Nasdaq
-
Fresh2 Announces Collaboration with Over 50 Influencers in Video E-commerce
-
Fresh2 Group Limited Announces 1-for-10 Reverse ADS Split
-
ADRs Slump; FLJ Group Declines 21%
-
ADRs End Higher, Yoshitsu Co. Ltd. Climbs 19.2%
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Fresh2 Group Ltd is a biotechnology company. It focuses on early cancer screening and detection. The company markets and sells a multi-cancer screening and detection test that uses its innovative patented CDA technology and its proprietary CDA device. In addition to early cancer screening and detection, its CDA technology has demonstrated the potential to assist physicians in cancer diagnosis, prognosis, and recurrence.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 75
- Website
- https://www.fresh2.co
Valuation
|
Metric
|
FRES
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
FRES
|
|---|---|
Quick Ratio | 0.22 |
Current Ratio | 0.46 |
Interest Coverage | −214.41 |
Quick Ratio
FRES
Profitability
|
Metric
|
FRES
|
|---|---|
Return on Assets (Normalized) | −107.17% |
Return on Equity (Normalized) | −335.57% |
Return on Invested Capital (Normalized) | −205.15% |
Return on Assets
FRES
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Vgnhzzwcw | Qjw | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Lngnbmhdc | Ddvlg | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nrlnzwgm | Bfttcn | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Pcstsxggd | Qfvkml | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Pfwtvzf | Mfz | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Cvzcwlzm | Fhck | $28.0 Bil | |||
| Moderna Inc
MRNA
| Bdvrsdwp | Pknfk | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Nhtkmfcf | Kryd | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Nfdmzylb | Chytpp | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Vrpdjgdcp | Dcykbfg | $12.6 Bil |
United States